Alzheimer's disease: Fatty acids we eat may be linked to a specific protection via low-dose aspirin

Aging and Disease

Volumn 1, Issue 1, 2010, Pages 37-59

  Pomponi, Massimo F L ^a   Gambassi, Giovanni ^a   Pomponi, Massimiliano ^a   Masullo, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Aspirin (ASA); Cytokines; Docosahexaenoic acid (DHA); Neuroprotectin D1 (NPD1); Nonsteroidal anti inflammatory drugs (NSAIDs); Primary prevention; Resolvins

Indexed keywords

EID: 84882639954     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: None     Document Type: Review

References (208)

1. Fagiolo U, Cossarizza A, Scala E, Fanales-Belasio E, Ortolani C, Cozzi E, Monti D, Franceschi C, Paganelli R (1993). Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol, 23:2375-378.
2. Giunta S (2006). Is inflammaging an auto[innate]immunity subclinical syndrome? Immun Ageing, 3:12.
3. Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhøj P, Pedersen BK (1999). A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci, 54:M357-64.
4. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC (2004). Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging, 25:663-74.
5. Alzheimer A (1910). Beiträge zur Kenntnis der pathologischen Neuroglia und ihrer Beziehungen zu den Abbauvorgängen im Nervengewebe. In: Nissl F, Alzheimer A (eds). Histologische und histopathologische Arbeiten über die Grosshirnrinde mit besonderer Berücksichtigung der pathologischen Anatomie der Geisteskrankheiten. Jena: Gustav Fischer, 401-562.
6. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J (2003). Adult mouse astrocytes degrade amyloid-ß in vitro and in situ. Nat Med, 9:453-57.
7. DeWitt DA, Perry G, Cohen M, Doller C, Silver J (1998). Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Exp Neurol, 149:329-40.
8. Rodríguez JJ, Olabarria M, Chvatal A, Verkhratsky A (2009). Astroglia in dementia and Alzheimer's disease. Cell Death Differ, 16:378-85.
9. Hansson E, Ronnback L (2003). Glial neuronal signaling in the central nervous system. FASEB J, 17:341-48.
10. Fields RD, Stevens-Graham B (2002). New insights into neuron-glia communication. Science, 298:556-62.
11. Ullian EM, Sapperstein SK, Christopherson KS, Barres BA (2001). Control of synapse number by glia. Science, 291: 657-61.
12. Etminan M, Gill S, Samii A (2003). Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ, 327:128.
13. Aisen PS, Schafer KA, Grundman M (2003). Effects of rofecoxib or naproxen versus placebo on Alzheimer disease progression: a randomized controlled trial. JAMA, 289:2819-26.
14. Thal LJ, Ferris SH, Korby L, Rofecoxib Protocol 078 Study Group (2005). A randomized double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology, 30:1204-1215.
15. Group AR, Lyketsos CG, Breitner JC (2007). Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology, 68:1800-808.
16. Serhan CN, Chiang N (2008). Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol, 153 Suppl 1:S200-15.
17. Groeger AL, Cipollina C, Cole MP, Woodcock SR, Bonacci G, Rudolph TK, Rudolph V, Freeman BA, Schopfer FJ (2010). Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. Nat Chem Biol, May 2.
18. Bazan N (2007). Omega-3 fatty acids, pro-inflammatory signalling and neuroprotection. Curr Opin Clin Nutr Metab Care, 10:136-41.
19. Jellinger KA, Bancher C (1998). Neuropathology of Alzheimer's disease: a critical update. J Neural Transm, 54 (Suppl.): S77-95.
20. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR (2000). Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev, 33:95-130.
21. Mosconi L, De Santi S, Rusinek H, Convit A, de Leon MJ (2004). Magnetic resonance and PET studies in the early diagnosis of Alzheimer's disease. Expert Rev Neurother, 4:831-49.
22. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME (2001). Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA, 286:2120-127
23. Small GW, Kepe V, Barrio JR (2006). Seeing is believing: neuroimaging adds to our understanding of cerebral pathology. Curr Opin Psychiatry, 19:564-69.
24. Lehericy S, Marjanska M, Mesrob L, Sarazin M, Kinkingnehun S (2006). Magnetic resonance imaging of Alzheimer's disease. Eur Radiol, 17:347-62.
25. Giannakopoulos P, Hof PR, Giannakopoulos AS, Herrmann FR, Michel JP, Bouras C (1995). Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of very old patients. Arch Neurol, 52:1150-159.
26. Mitchell TW, Mufson EJ, Schneider JA, Cochran EJ, Nissanov J, Han LY, Bienias JL, Lee VM, Trojanowski JQ, Bennett DA, Arnold SE (2002).Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol, 51:182-89.
27. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416:535-39.
28. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001). Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science, 93:1487-491.
29. Golde TE (2003). Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest, 111:11-18.
30. Breteler MM (2000). Vascular involvement in cognitive decline and dementia: epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study, Ann NY Acad Sci, 903: 457-65.
31. De la Torre JC (2004). Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol, 3:184-90.
32. Zhao Y, Cui JG, Lukiw WJ (2006). Natural secretory products of human neural and microvessel endothelial cells: Implications in pathogenic "spreading" and Alzheimer's disease. Mol Neurobiol, 34:181-92.
33. Hardy J, Selkoe DJ (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297:353-56.
34. Daulatzai MA (2010). Early Stages of Pathogenesis in Memory Impairment during Normal Senescence and Alzheimer's Disease. J Alzheimers Dis. Feb 17. [Epub ahead of print].
35. Csiszar A, Wang M, Lakatta EG, Ungvari Z (2008). Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J Appl Physiol, 105:1333-341.
36. Salminen A, Huuskonen J, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T (2008). Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res Rev, 7:83-105.
37. Gautam R, Jachak SM (2009). Recent developments in anti-inflammatory natural products. Med Res Rev, 29:767-820.
38. Youn J, Lee JS, Na HK, Kundu JK, Surh YJ (2009). Resveratrol and piceatannol inhibit iNOS expression and NF-kappa B activation in dextran sulfate sodium-induced mouse colitis. Nutr Cancer, 61:847-54.
39. Aggarwal, BB (2003). Signaling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol, 3: 745-56.
40. Chen F, Castranova V, Shi X, Demers LM (1999). New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem, 45:7-17.
41. Tansey MG, Wyss-Coray T. Cytokines in CNS inflammation and disease. In: Lane TE, Carson M, CB, T W-C, editor. Central Nervous System Diseases and Inflammation. W-C: Springer; 2008.
42. Merrill JE (1991). Effects of interleukin-1 and tumor necrosis factor-alpha on astrocytes, microglia, oligodendrocytes, and glial precursors in vitro. Dev Neurosci, 13:130-37.
43. Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, Beattie MS, Malenka RC (2002). Control of synaptic strength by glial TNFalpha. Science, 295:2282-285.
44. Mattson MP, Barger SW, Furukawa K, Bruce AJ, Wyss-Coray T, Mark RJ, Mucke L (1997). Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res Brain Res Rev, 23:47-61.
45. Lieberman AP, Pitha PM, Shin HS, Shin ML (1989). Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci USA, 86, 6348-6352.
46. Chung IY & Benveniste EN (1990). Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J Immunol 144, 2999-3007.
47. Morganti-Kossman MC, Lenzlinger PM, Hans V, Stahel P, Csuka E, Ammann E, Stocker R, Trentz O, Kossmann T (1997). Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. Mol Psychiatry 2, 133-136.
48. Pickering M, Cumiskey D, O'Connor JJ (2005). Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol, 90:663-70.
49. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T, Suzumura A (2006). Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem, 281:21362-368.
50. Mayhan WG (2002). Cellular mechanisms by which tumor necrosis factor-alpha produces disruption of the blood-brain barrier. Brain Res, 927(2):144-52.
51. Bruunsgaard H, Skinhoj P, Pedersen AN., Schroll M, Pedersen BK(2000). Ageing, tumour necrosis factor-a (TNF-a) and atherosclerosis. Clin. Exp. Immunol, 121:255-60.
52. Pedersen M, Bruunsgaard H, Weis N, Hendel HW, Andreassen BU, Eldrup E, Dela F, Pedersen BK (2003). Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev, 124:495-502.
53. Wu D, Meydani SN (2008). Age-associated changes in immune and inflammatory responses: impact of vitamin E intervention. J Leukoc Biol. 84:900-14.
54. Zhang C, Xu X, Potter BJ Wang W, Kuo L, Michael L, Bagby GJ, Chilian WM (2006). TNF-a contributes to endothelial dysfunction in ischemia/reperfusion injury. Arterioscler. Thromb. Vasc. Biol, 26:475-80.
55. Zhang H, Park Y, Wu J, Chen X, Lee S, Yang J, Dellsperger KC, Zhang C (2009). Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond), 116:219-30.
56. Csiszar A, Labinskyy N, Smith K, Rivera A, Orosz Z, Ungvari Z (2007). Vasculoprotective effects of anti-tumor necrosis factor-a treatment in aging. Am J Pathol, 170:388-98.
57. Mehlhorn G, Hollborn M, Schliebs R (2000). Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci, 18:423-31.
58. Gao X, Belmadani S, Picchi A, Xu X, Potter BJ, Tewari-Singh N, Capobianco S, Chilian WM, Zhang C (2007). Tumor necrosis factor-a induces endothelial dysfunction in Lepr(db) mice. Circulation, 115:245-54.
59. Lukiw WJ(2004). Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling. Neurochem. Res, 29:1287-297.
60. Streit W. J., Sammons N. W., Kuhns A. J. and Sparks D. L. (2004). Dystrophic microglia in the aging human brain. Glia 45, 208-212. Godbout J. P. and Johnson R. W. (2004) Interleukin-6 in the aging brain. J. Immunol, 147:141-44.
61. Godbout JP, Johnson RW (2004). Interleukin-6 in the aging brain. J Neuroimmunol, 147:141-44.
62. Miller KR, Streit WJ (2007). The effects of aging, injury and disease on microglial function: a case for cellular senescence. Neuron Glia Biol, 3:245-53.
63. Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE (2002). Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology, 59:371-78.
64. Alexopoulou L, Holt A C, Medzhitov R, Flavell RA (2001). Recognition of double-stranded RNA and activation of NF-?B by Toll-like receptor 3. Nature 413, 732-38.
65. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L, Aderem A. (2000). The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Natl Acad. Sci. USA, 97:13766-3771.
66. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000). Inflammation and Alzheimer's disease. Neurobiol Aging, 21:383-421.
67. Griffin WS, Sheng JG, Roberts GW, Mrak RE (1995). Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol, 54:276-81.
68. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, Nilsson LN (1999). Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences. J Biol Chem, 274:6421-431.
69. Richartz E, Batra A, Simon P, Wormstall H, Bartels M, Buchkremer G, Schott K (2005). Diminished production of pro-inflammatory cytokines in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord, 19:184-88.
70. Lombardi VR, García M, Rey L, Cacabelos R (1999). Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals. J Neuroimmunol, 97:163-71.
71. Sala G, Galimberti G, Canevari C, Raggi ME, Isella V, Facheris M, Appollonio I, Ferrarese C (2003). Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol. Aging, 24:909-14
72. Galimberti D, Fenoglio C, Lovati C, Venturelli E, Guidi I, Corra B, Scalabrini D, Clerici F, Mariani C, Bresolin N, Scarpini E (2006). Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol. Aging, 27:1763-768.
73. Huberman M, Shalit F, Roth-Deri I, Gutman B, Brodie C, Kott E, Sredni B (1994). Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J Neuroimmunol, 52:147-52.
74. McGeer PL, McGeer EG (2007). NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies, Neurobiol. Aging, 28:639-47.
75. Vlad SC, Miller DR, Kowall NW, Felson DT (2008). Protective effects of NSAIDs on the development of Alzheimer disease. Neurology, 70:1672-677.
76. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A (1995). Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology. 45:1441-45.
77. McGeer PL, Schulzer M, McGeer EG (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology, 47:425-32.
78. Stewart WF, Kawas C, Corrada M, Metter EJ (1997). Risk of Alzheimer's disease and duration of NSAID use. Neurology, 48:626-32.
79. Anthony JC, Breitner JC, Zandi PP, Meyer MR, Jurasova I, Norton MC, Stone SV (2000). Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology, 54:2066-71.
80. In t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH (2001). Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med, 345:1515-521.
81. Szekely CA, Green RC, Breitner JC, Østbye T, Beiser AS, Corrada MM, Dodge HH, Ganguli M, Kawas CH, Kuller LH, Psaty BM, Resnick SM, Wolf PA, Zonderman AB, Welsh-Bohmer KA, Zandi PP (2008). No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology, 70:2291-8.
82. Pasinetti GM, Pompl PN (2002). Cyclo-oxygenase inhibitors and Alzheimer's: are we well ADAPTed? Lancet Neurol, 1:403-04.
83. Varvel NH, Bhaskar K, Kounnas MZ, Wagner SL, Yang Y, Lamb BT, Herrup K (2009). NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest, 119:3692-702.
84. Ubogu EE (2006). The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci, 27:48-55.
85. Yoshimura T (1987) Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA, 84:9233-237.
86. Akama KT, Van Eldik LJ (2000). B-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1ß- and tumor necrosis factor-a (TNF-a)-dependent, and involves a TNF-a receptor-associated factor- and NF-?B-inducing kinase-dependent signaling mechanism. J Biol Chem, 275:7918-24.
87. McGeer PL, McGeer EG (2004). Inflammation and degenerative disease of aging. Ann NY Acad Sci, 1035:104-16.
88. Shie FS, Breyer RM, Montine TJ (2005). Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am J Pathol, 166:1163-172.
89. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M (2008). Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol, 65:896-905.
90. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC (2004). Rofecoxib Protocol 091 Study Group. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology, 62:66-71.
91. Moncada S, Ferreira SH, Vane JR. (1975). Inhibition of prostaglandin biosynthesis as the mechanism of analgesia of aspirin-like drugs in the dog knee joint. European J Pharmacol, 31:250-60.
92. He J, Whelton PK, Vu B, Klag MJ (1998). Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA, 280:1930-935.
93. Patrono C, Rocca B (2009). Aspirin, 110 years later. J Thromb Haemost, 7 (Suppl):S258S-61.
94. JBS2 working party (2005). Joint British Societies? guidelines on prevention of cardiovascular disease in clinical practice. Heart, 91(Suppl 5): v1-52.
95. Patrono C, Garcia Rodríguez LA, LandolfiR, and Baigent C (2005). Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med, 353:2373-383.
96. Patrono C, Baigent C, Hirsh J, Roth G (2008). Antiplatelet drugs: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest, 133 (Suppl):199S-233.
97. Bartolucci A, Howard G (2006). Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol, 98:746-50.
98. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL (2006). Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA, 295:306-13.
99. Antithrombotic Trialists' Collaboration (2002). Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ, 324:71-86.
100. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S (2003). Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation, 108:1682-687.
101. James MJ, Gibson RA, Cleland LG (2000). Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr, 71(1 Suppl):S343-48.
102. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, Schneider J (2003). Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol, 60:940-46.
103. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PW, Wolf PA (2006). Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol, 63:1545-550.
104. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N Jr, Stedman M; on behalf of the MIDAS Investigators (2010). Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement, Apr 29. [Epub ahead of print]
105. Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D, Gibney MJ (2003). Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr, 89:483-89.
106. Kyle DJ, Schaefer E, Patton G, Beiser A (1990). Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids, 34(Suppl):S245.
107. Soderberg M, Edlund C, Kristensson K, Dallner G (1991). Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids, 26:421-25.
108. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM (1997). Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann Neurol, 42:776-82.
109. Nourooz-Zadeh J, Liu EH, Yhlen B, Anggard EE, Halliwell B (1999). F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem, 72:734-40.
110. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD (2005). Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol, 58:730-35.
111. Quinn JF, Raman R, Thomas RG, Ernstrom K, Yurko-Mauro K, Nelson EB, Shinto L, Nair AK, Aisen PS (2009). A clinical trial of docosahexanoic acid (DHA) for the treatment of Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 5:84S.
112. Calderon F, Kim HY (2004). Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem, 90:979-88.
113. Darios, F., Davletov, B (2006). Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3. Nature, 440: 813-17.
114. Lawson DL, Mehta JL, Saldeen K, Mehta P, Saldeen TG (1991). Omega-3 polyunsaturated fatty acids augment endothelium-dependent vasorelaxation by enhanced release of EDRF and vasodilator prostaglandins. Eicosanoids, 4:217-23.
115. Pomponi M, Bria P, Pomponi M (2008). Is Alzheimer's disease a synaptic disorder? J Alzheimers Dis, 13:39-47.
116. Bazan NG (2009). Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot Essent Fatty Acids, 81:205-11.
117. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA (1997). Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem, 272:3406-410.
118. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, van Leuven F, Heneka MT (2006). Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA, 103:443-48.
119. Sundararajan S, Landreth GE (2004). Anti-inflammatory properties of PPARgamma agonists following ischemia. Drug News Perspect, 17:229-36.
120. Del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ (2000). Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 10:95-112.
121. Yoo HY, Chang MS, RhoHM (1999) Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferator-responsive element by arachidonic acid. Gene, 234:87-91.
122. Girnun GD, Domann FE, Moore SA, Robbins ME (2002). Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol, 16:2793-801.
123. Park EY, Cho IJ, Kim SG (2004). Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. Cancer Res, 64:3701-713.
124. Guillot N, Debard C, Calzada C, Vidal H, Lagarde M, Véricel E (2008). Effects of docosahexaenoic acid on some megakaryocytic cell gene expression of some enzymes controlling prostanoid synthesis. Biochem Biophys Res Commun, 372:924-28.
125. Dudek H, Datta SR, Franke TF, Birnbaum MJ. Yaou R, Cooper GM, Segal R A, Kaplan DR, Greenberg M E (1997). Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science, 275:661-65.
126. Segal RA (2003). Selectivity in neurotrophin signaling: theme and variations. Annu Rev Neurosci, 26:299-330.
127. Akbar M, Calderon F, Wen Z, Kim HY (2005). Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci U S A, 102:10858-63.
128. Chapkin RS, Kim W, Lupton JR, McMurray DN (2009). Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot Essent Fatty Acids, 81:187-91.
129. Olson JK, Miller SD (2004). Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol, 173:3916-924.
130. Bowman CC, Rasley A, Tranguch SL, Marriott I (2003). Cultured astrocytes express toll-like receptors for bacterial products. Glia, 43:281-91.
131. Bsibsi M, Ravid R, Gveric D, van Noort JM (2002). Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol, 61:1013-021.
132. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, Lathia JD, Siler DA, Chigurupati S, Ouyang X, Magnus T, Camandola S, Mattson MP (2007). Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A, 104:13798-803.
133. Bazan NG, Calandria JM, Serhan CN (2010). Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1. J Lipid Res, Apr 9.
134. Bazan NG, Birkle DL, Reddy TS (1984). Docosahexaenoic acid (22:6, n-3) is metabolized to lipoxygenase reaction products in the retina. Biochem. Biophys. Res. Commun. 125: 741-47.
135. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG (2004). Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A, 101:8491-496.
136. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, Hardy M, Gimenez JM, Chiang N, Serhan CN, Bazan NG (2003). Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem, 278:43807-3817.
137. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG (2005). A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest, 115:2774-783.
138. Zhang C, Bazan NG (2010). Lipid-Mediated Cell Signaling Protects against Injury and Neurodegeneration. J Nutr, 140: 858-63.
139. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE (2003). NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest, 112:440-49.
140. Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J (2008). Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol, 7:41-9.
141. Rapoport SI (2008). Arachidonic acid and the Brain. Symposium: Dietary PUFA and the Aging Brain- Food for Thought. J Nutr, 2515-520.
142. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN (2003). Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem, 278:14677-687.
143. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006). Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol, 63:1402-408.
144. Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S (2002). Fish, meat, and risk of dementia: cohort study. BMJ, 325:932-33.
145. Yurko-Mauro K, Nelson EB, Secker D (2007). Memory improvement with docosahexaenoic acid study (MIDAS). Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 3(Suppl):S123.
146. Gamoh S, Hashimoto M, Sugioka K, Shahdat Hossain M, Hata N, Misawa Y, Masumura S (1999). Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience, 93:237-41.
147. McGahon BM, Martin DS, Horrobin DF, Lynch MA (1999). Age-related changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience, 94:305-14.
148. Mirnikjoo B, Brown SE, Kim HF, Marangell LB, Sweatt JD, Weeber EJ (2001). Protein kinase inhibition by omega-3 fatty acids. J Biol Chem, 276:10888-896.
149. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M (2000). Polyunsaturated fatty acids are potent neuroprotectors. EMBO J, 19:1784-793.
150. Rodriguez de Turco EB, Belayev L, Liu Y, Busto R, Parkins N, Bazan NG, Ginsberg MD (2002). Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin. J Neurochem, 83:515-24.
151. Thompson WL, Van Eldik LJ (2009). Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected]. Brain Res, 1287:47-57.
152. D'Mello C, Le T, Swain MG (2009). Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J Neurosci, 29:2089-102.
153. Perry VH (2004). The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease, Brain Behav Immun, 18:407-13.
154. Teeling JL, Perry VH (2009). Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms, Neuroscience 158:1062-073.
155. Quan N, Whiteside M, Herkenham M (1998). Time course and localization patterns of interleukin-1beta messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide. Neuroscience, 83:281-93.
156. van Gool WA, van de Beek D, Eikelenboom P (2010). Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet, 375:773-75.
157. Vitkovic L, Konsman JP, Bockaert J, Dantzer R, Homburger V, Jacque C (2000). Cytokine signals propagate through the brain. Mol Psychiatry, 5: 604-15.
158. Banks WA (2006). The blood-brain barrier in psychoneuroimmunology. Neurol Clin,24:413-19.
159. Quan N, Banks WA (2007). Brain-immune communication pathways, Brain Behav Immun, 21: 727-35.
160. Konsman, JP, Vigues S, Mackerlova L, Bristow A, Blomqvist A (2004). Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J Comp Neurol 472:113-29.
161. Schiltz JC, Sawchenko PE (2002). Distinct brain vascular cell types manifest inducible cyclooxygenase expression as a function of the strength and nature of immune insults. J Neurosci, 22:5606-618.
162. Hoshino T, Namba T, Takehara M, Nakaya T, Sugimoto Y, Araki W, Narumiya S, Suzuki T, Mizushima T (2009). Prostaglandin E2 stimulates the production of amyloid-beta peptides through internalization of the EP4 receptor. J Biol Chem, 284:18493-502.
163. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS (2001). Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA, 286:1187-194.
164. Rosenberg IH (2002). Fish-food to calm the heart. N Engl J Med, 346:1102-103.
165. Cole GM, Frautschy SA (2006). Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model. Nutr Health, 18(3):249-59.
166. Dal Bianco A, Bradl M, Frischer J, Kutzelnigg A, Jellinger K, Lassmann H (2008). Multiple sclerosis and Alzheimer's disease. Ann Neurol, 63:174-83.
167. Serhan C, Chiang N and Van Dyke T (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol, 8:349-61.
168. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K (2000). Novel functional sets of lipid-derived mediators with anti-inflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal anti-inflammatory drugs and transcellular processing. J Exp Med, 192:1197-204.
169. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac RL (2002). Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med, 196:1025-037.
170. Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P (2008). Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des, 14:1419-427.
171. Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH, Hong S, Serhan CN (2005). Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol, 174:4345-55.
172. Nilsson SE, Johansson B, Takkinen S, Berg S, Zarit S, McClearn G, Melander A (2003). Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged > or =80 years. Eur J Clin Pharmacol, 59:313-19.
173. Sun YP, Oh SF, Uddin J, Yang R, Gotlinger K, Campbell E, Colgan, SP, Petasis NA, Serhan CN (2004). Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem, 282:9323-334.
174. Pamplona FA, Menezes-de-Lima O Jr, Takahashi RN (2010). Aspirin-triggered lipoxin induces CB1-dependent catalepsy in mice. Neurosci Lett, 470:33-7.
175. Serhan CN, Oliw E (2001). Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. J Clin Invest, 107:1481-89.
176. Zingarelli B, Sheehan M, Hake PW, O'Connor M, Denenberg A, Cook JA. Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol. 2003 Dec 15;171(12):6827-37.
177. Malur A, Mccoy AJ, Arce S, Barna BP, Kavuru MS, Malur AG, Thomassen MJ (2009). Deletion of PPAR gamma in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response. J. Immunol,. 182:5816-822.
178. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH (2009). Systemic inflammation and disease progression in Alzheimer disease. Neurology, 73(10):768-74.
179. Salminen A, Kauppinen A, Suuronen T, Kaarniranta K, Ojala J (2009). ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology. J Neuroinflammation, 6:41.
180. Citron M, Teplow DB, Selkoe DJ (1995). Generation of amyloid beta protein from its precursor is sequence-specific. Neuron 14:661-670.
181. Selkoe DJ (2001). Alzheimer's disease: genes, proteins and therapies. Physiol Rev, 81:742-61.
182. Tan J, Town T, Mori T, Wu Y, Saxe M, Crawford F, Mullan M (2000). CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J Neurosci, 20(20):7587-94.
183. Chong YH, Shin SA, Lee HJ, Kang JH, Suh YH (2002). Molecular mechanisms underlying cyclic AMP inhibition of macrophage dependent TNF-alpha production and neurotoxicity in response to amyloidogenic C-terminal fragment of Alzheimer's amyloid precursor protein. J Neuroimmunol, 133:160-74.
184. Rivest S (2009). Regulation of innate immune responses in the brain. Nat Rev Immunol, 9(6):429-39.
185. Ungvari Z, Orosz Z, Labinskyy N, Rivera A, Xiangmin Z, Smith K, Csiszar A (2007). Increased mitochondrial H2O2 production promotes endothelial NF-kappaB activation in aged rat arteries. Am J Physiol Heart Circ Physiol, 293: H37-H47.
186. Yoon HJ, Cho SW, Ahn BW, Yang SY (2010). Alterations in the activity and expression of endothelial NO synthase in aged human endothelial cells. Mech Ageing Dev, 13:119-23.
187. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I (2002). Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation, 105:1541-44.
188. Taubert D, Berkels R, Grosser N, Schröder H, Gründemann D, Schömig E (2004]. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol, 143:159-65.
189. Lee M, Schwab C, Yu S, McGeer E, McGeer PL (2009). Astrocytes produce the anti-inflammatory and neuroprotective agent hydrogen sulfide. Neurobiol Aging, 30:1523-34.
190. Dunn JA, Patrick JS, Thorpe SR, Baynes JW (1989). Oxidation of glycated proteins: age-dependent accumulation of N epsilon-(carboxymethyl)lysine in lens proteins. Biochemistry, 28:9464-8.].
191. Van der Loo B, Labugger R, Skepper JN, Bachschmid M, Kilo J, Powell JM, Palacios-Callender M, Erusalimsky JD, Quaschning T, Malinski T, Gygi D, Ullrich V, Lüscher TF (2000) Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med, 192, 1731-44.
192. Szmitko PE, Wang CH, Weisel RD, Jeffries GA, Anderson TJ, Verma S (2003). Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation, 108:2041-48.
193. McCoy MK, Tansey MG (2008). TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation, 5:45.
194. Spiekermann S, Landmesser U, Dikalov S, Bredt M, Gamez G, Tatge H, Reepschläger N, Hornig B, Drexler H, Harrison DG (2003). Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation, 107(10):1383-89.
195. Lind L, Siegbahn A, Hulthe J, Elmgren A (2008). C-reactive protein and e-selectin levels are related to vasodilation in resistance, but not conductance arteries in the elderly: the prospective investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis, 199:129-37.
196. Hoffmann J, Haendeler J, Aicher A, Rössig L, Vasa M, Zeiher AM, Dimmeler S (2001). Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: important role of nitric oxide. Circ Res, 89:709-15.
197. Bhagat K, Vallance P (1997). Inflammatory cytokines impair endothelium-dependent dilation in human veins in vivo. Circulation, 96: 3042-47.
198. Goodwin, BL, Pendleton LC, Levy MM, Solomonson LP, Eichler DC. (2007) Tumor necrosis factor-a reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. Am J Physiol Heart Circ Physiol, 293: H1115-H1121.
199. Smith W, Garavito R, DeWitt D (1996). Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem, 271:33157-60.
200. Kawasaki M, Yoshihara Y, Yamaji M, WatanabeY (1993). Expression of prostaglandin endoperoxide synthase in rat brain, Brain Res Mol Brain Res 19:39-46.
201. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P (1996). COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex, Proc Natl Acad Sci. USA, 93: 2317-21.
202. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr, Libby P (1994). The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and pro-inflammatory proteins in human endothelial cells. Arterioscler Thromb, 14:1829-36.
203. Ebert S, Weigelt K, Walczak Y, Drobnik W, Mauerer R, Hume DA, Weber BH, Langmann T (2009). Docosahexaenoic acid attenuates microglial activation and delays early retinal degeneration. J Neurochem, 110:1863-75.
204. Musiek ES, Brooks JD, Joo M, Brunoldi E, Porta A, Zanoni G, Vidari G, Blackwell TS, Montine TJ, Milne GL, McLaughlin B, Morrow JD (2008). Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. J Biol Chem, 283:19927-35.
205. Singer P, Shapiro H, Theilla M, Anbar R, Singer J, Cohen J (2008). Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive Care Med, 34:1580-92.
206. Marcheselli VL, Mukherjee PK, Arita M, Hong S, Antony R, Sheets K, Winkler JW, Petasis NA, Serhan CN, Bazan NG (2010). Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot Essent Fatty Acids, 82:27-34.
207. Marion-Letellier R, Butler M, Déchelotte P, Playford RJ, Ghosh S (2008). Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells--potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation. Am J Clin Nutr, 87:939-48.
208. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M (2009). Maresins: novel macrophage mediators with potent anti-inflammatory and proresolving actions. J Exp Med, 206:15-23.